Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Halozyme Therapeutics Inc HALO

Healthcare Biotechnology
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Company’s ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on... see more

Recent & Breaking News (NDAQ:HALO)

Halozyme To Participate In 2019 Wells Fargo Healthcare Conference

PR Newswire August 26, 2019

Halozyme Reports Second Quarter 2019 Results

PR Newswire August 6, 2019

Halozyme To Participate In 39th Annual Canaccord Genuity Growth Conference

PR Newswire July 25, 2019

Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call

PR Newswire July 23, 2019

Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology

PR Newswire July 19, 2019

Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology

PR Newswire July 17, 2019

Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology

PR Newswire July 12, 2019

Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology

PR Newswire June 25, 2019

Halozyme To Participate In Upcoming Investor Conferences

PR Newswire June 4, 2019

Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement

PR Newswire May 22, 2019

Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019

PR Newswire May 13, 2019

Halozyme Reports First Quarter 2019 Results

PR Newswire May 7, 2019

Halozyme Names Dr. Alison A. Armour As Senior Vice President Of Research And Development

PR Newswire May 6, 2019

REPEAT/Halo Labs Begins Trading on the OTCQX Market

Press Releases April 30, 2019

REPEAT/Halo Labs Begins Trading on the OTCQX Market

Business Wire April 30, 2019

Halo Labs Begins Trading on the OTCQX Market

Business Wire April 30, 2019

Halo Labs Begins Trading on the OTCQX Market

Press Releases April 30, 2019

Halozyme To Host First Quarter 2019 Financial Results Webcast And Conference Call

PR Newswire April 23, 2019

Halozyme To Participate In Upcoming Investor Conferences

PR Newswire March 4, 2019

Halozyme Announces FDA Approval Of Herceptin Hylecta™

PR Newswire February 28, 2019